Diabetes Type One in Pregnancy and Continuos Glucose Monitoring

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-11

Study Completion Date

2024-01-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Type I diabetes mellitus (T1DM) affects about 0.1-0.2% of all pregnancies. T1DM in pregnancy increases the risk of maternal and neonatal complications.

Continuous glucose monitoring systems (CGM) provide a continuous display of measured glucose. Studies have shown improved pregnancy outcomes for patients with T1DM using CGM when compared to capillary blood glucose measurements.

This prospective observational study analyses impact of glycemic variability on development of large-for-gestational-age neonates and effects of hypoglycemia during pregnancy on pregnancy outcomes.

Furthermore, overall glycemic regulation, different insulin metrics and C-peptide concentration during pregnancy will also be assesed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Real-time Continuous Glucose Monitoring on Severe Complications to Pregnancy in Women With Diabetes

NCT00994357

Diabetes Pregnancy

COMPLETED NA

Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial

NCT01788527

Type 1 Diabetics Who Are Pregnant or Planning Pregnancy

COMPLETED NA

Correlation of CGM Metrics With OGTT and Pregnancy Outcomes in Pregnant Women With or Without a High Risk for GDM

NCT05537480

Pregnancy Complications Diabetes Mellitus Hyperglycemic Disorder

UNKNOWN NA

Pregnancy and Postpartum CGM in GDM

NCT07174245

Gestational Diabetes

RECRUITING

Time Spent In Target Glucose Range in Women With T2D Diabetes in Pregnancy

NCT06147466

Diabete Type 2 Pregnancy in Diabetic

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Up to 200 patients with type one diabetes will be enrolled in the study during first trimester of pregnancy. Medical history, clinical examination, anthropometric measurements and laboratory work-up will be obtained at first visit. Glucose metrics are provided from continuous glucose monitoring systems and blood glucose measurements .

Following the initial evaluation, patients will be regularly examined in the hospital setting once a month during pregnancy. Following evaluations will include the same procedures as the first one.

Pregnancy outcomes that will be analysed: spontaneous abortion, preterm birth, large-for-gestational-age neonates, macrosomia, small-for-gestational-age neonates, birth weight, congenital anomalies, APGAR score, neonatal hypoglycemia, intensive care unit admission for mother and/or infant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Large-for-gestational-age Neonates Glycemic Variability Hypoglycemia Pregnancy Outcomes C-peptide

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed diagnosis of type one diabetes
* duration of the disease for minimum of one year before inclusion in the study
* multiple daily insulin injection therapy or insulin pump
* glycemia monitoring with continuous glucose monitoring systems (FreeStyle Libre Flash Glucose Monitoring System, Abott) for a minimum of 3 months before inclusion in the study
* glucose data availability from the sensor \> 80% for a determined period of monitoring
* patient age \> 18 years and \< 40 years
* available medical records from the preconception period (3 months before conception)
* first trimester of pregnancy
* body mass index \< 25kg/m2
* glycated haemoglobin \< 7.0%
* signed informed consent

Exclusion Criteria

* other types of diabetes except type one: type 2 diabetes, diabetes developed during pregnancy, diabetes as a result of genetic defect of beta-cells of the pancreas
* using other therapy besides insulin in treating diabetes
* changes to the specific insulin therapy in preconception period or during pregnancy; defined as switching from multiple daily insulin injection therapy to insulin pumps and vice versa
* patient's inability for regular hospital visits (defined as once monthly during pregnancy)
* patients unable to understand the protocol and the goal of the study
* patients unable to read and write
* multiple pregnancy
* glycated haemoglobin \> 7.0% in all pregnancy trimesters
* significant weight gain during pregnancy (\>20 kilograms)
* glucose data availability from the sensor \< 80%
* unavailability of preconception medical records
* unavailability of medical records from pregnancy and pregnancy outcomes

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No